Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q3 2018 · 10-Q
Revenue$103.00M$103.00M+28.1% vs Q3 2017 Net Income$28.01M$28.01M+75.5% vs Q3 2017 EPS Diluted$0.52$0.52+79.3% vs Q3 2017 Operating Income$37,475,000+67.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$62,257,000+61.4% Margins · derivedOperating margin36.4%+8.6 pt vs Q3 2017
Net margin27.2%+7.3 pt vs Q3 2017
ended Sep 30, 2018 · filed Nov 9, 2018 · 40 d after period end